These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8652366)

  • 61. [Rapid drug information].
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):506-7. PubMed ID: 15830265
    [No Abstract]   [Full Text] [Related]  

  • 62. Bisphosphonates: biological response modifiers in breast cancer.
    Paterson AH
    Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Bisphosphonates in the treatment and prevention of bone metastases].
    Hoekman K; van Holten-Verzantvoort AT; Pinedo HM
    Ned Tijdschr Geneeskd; 1997 Nov; 141(46):2217-22. PubMed ID: 9550782
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dichloromethylene diphosphonate action in hematologic and other malignancies.
    Canfield RE; Siris ES; Jacobs TP
    Bone; 1987; 8 Suppl 1():S57-62. PubMed ID: 2961356
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
    Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
    Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.
    McCloskey EV; Guest JF; Kanis JA
    Drugs; 2001; 61(9):1253-74. PubMed ID: 11511021
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 68. Bisphosphonates for malignancy-related bone disease: current status, future developments.
    Body JJ
    Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
    Body JJ
    Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Bone metastases and hypercalcemia in cancer].
    Body JJ; Glibert F; Nejai S; Borkowski A
    Rev Med Liege; 1988 Mar; 43(6):190-3. PubMed ID: 3375643
    [No Abstract]   [Full Text] [Related]  

  • 71. [Bisphosphonates-induced osteonecrosis of the jaw: CT-findings].
    Maksimovic O; Denecke B; Pintoffl JP; Horger M
    Rofo; 2008 Apr; 180(4):277-9. PubMed ID: 18432565
    [No Abstract]   [Full Text] [Related]  

  • 72. [Tumorous osteopathy and tumorous hypercalcemia].
    Thiébaud D; Burckhardt P
    Internist (Berl); 1990 Dec; 31(12):756-62. PubMed ID: 2289865
    [No Abstract]   [Full Text] [Related]  

  • 73. Bisphosphonates and bone metastases: current status and future directions.
    Krempien R; Niethammer A; Harms W; Debus J
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):295-305. PubMed ID: 15877526
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
    Dallas SL; Garrett IR; Oyajobi BO; Dallas MR; Boyce BF; Bauss F; Radl J; Mundy GR
    Blood; 1999 Mar; 93(5):1697-706. PubMed ID: 10029599
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is long-term bisphosphonate administration associated with significantly increased circulating parathormone levels in patients with multiple myeloma?
    Cook G
    Eur J Endocrinol; 2003 Nov; 149(5):467-8. PubMed ID: 14585097
    [No Abstract]   [Full Text] [Related]  

  • 77. Update on the pharmacological prevention of skeletal-related events in cancer patients.
    Kennedy K; Patel H
    Orthopedics; 2011 Dec; 34(12):982-5. PubMed ID: 22147215
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Bisphosphonates. Drugs for the treatment of disorders of calcium and bone metabolism].
    Warneke G; Henning HV
    Internist (Berl); 1992 Jun; 33(6):441-5. PubMed ID: 1385800
    [No Abstract]   [Full Text] [Related]  

  • 80. How can we improve the treatment of bone metastases further?
    Coleman RE
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S7-13. PubMed ID: 9801853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.